Compare General Dynamics Corporation (GD) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Medtronic PLC — how do they compare? General Dynamics Corporation trades at $331.32 (market cap $89.26B), while Medtronic PLC trades at $87.9 (market cap $112.24B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Medtronic PLC for 63 Days on average.
| GD | MDT | |
|---|---|---|
Market Cap | $89.26B | $112.24B |
Volume | 1,496,273 | 105,663,236 |
Sector | Industrials | Health |
52-Week High | $395.97 | $105.35 |
52-Week Low | $312.53 | $73.75 |
Typical Hold Time | 85 Days | 63 Days |
Enterprise Value | $94.40B | $131.58B |
Dividend Yield | 1.93% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $326.63, down 1.42% with bearish technical signals despite strong fundamentals. The defense contractor shows consistent revenue growth to $52.55B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with a $420.57 price target, supported by robust Pentagon spending and dividend reliability. Technical indicators show oversold conditions with RSI at 11.03, though moving averages signal bearish momentum.
GD presents a compelling value opportunity with attractive valuation metrics (P/E 19.92) and strong cash flow generation. Key risks include defense budget volatility and execution challenges, but the company's record backlog and dividend stability provide downside protection. The stock offers 28% upside to consensus targets with defensive characteristics suitable for long-term investors.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
